Aveo's Tivozanib Under CHMP Spotlight If Negative OS Trend Continues In TIVO-3

 
• By John Davis
  
GreenPawn
Improved survival is a key measure for regulators and patients alike. • Source: Shutterstock

More from Anticancer

More from Therapy Areas